Program
azvudine
Also written as “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)”, “Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)” and “Azvudine tablets(FNC) and Rifampicin Capsules (RIF)”.
Its studies are mostly in COVID-19 · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Henan Genuine Biotech | 81 open or running | phase 1since May 8, 2025 | May 8, 2025 | none ahead |
| Fosun Pharma | 20 open or running | phase 3since Nov 30, 2022 | Nov 30, 2022 | none ahead |
Also a collaborator on its studies: henan-sincere-biotech-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2022First study: phase 3 study in COVID-19New to Fosun PharmaFosun Pharma · NCT05633433 · 1,550 enrolled · Malaysia, Philippines
- Jan 10, 2023Phase 2 study in COVID-19Fosun Pharma · NCT05682599 · 300 enrolled · China
- May 8, 2025Henan Genuine Biotech's first studies: 8 phase 1 studiesNew to Henan Genuine BiotechHenan Genuine Biotech · NCT06991634, NCT07002281, NCT07002255 and 5 more
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Reverse transcriptase inhibitor; Replicase polyprotein 1ab inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07001501Healthy · China | 1 | Completed | Henan Genuine Biotech | Apr 25, 2022 | 15 |
| NCT07001488Healthy · China | 1 | Completed | Henan Genuine Biotech | May 1, 2022 | 15 |
| NCT07001436Renal Insufficiency · China | 1 | Recruiting | Henan Genuine Biotech | Aug 30, 2025 | 40 |
| NCT07002281Healthy · China | 1 | Completed | Henan Genuine Biotech | Oct 10, 2024 | 6 |
| NCT07002255Healthy · China | 1 | Completed | Henan Genuine Biotech | Mar 22, 2022 | 15 |
| NCT07002242Healthy · China | 1 | Completed | Henan Genuine Biotech | Aug 25, 2022 | 15 |
| NCT07002229Healthy · China | 1 | Completed | Henan Genuine Biotech | Feb 23, 2022 | 15 |
| NCT06991634Healthy · China | 1 | Completed | Henan Genuine Biotech | Apr 27, 2023 | 24 |
| NCT05682599COVID-19 · China | 2 | UNKNOWN | Fosun Pharma | Apr 15, 2023 | 300 |
| NCT05633433COVID-19 · Malaysia, Philippines | 3 | UNKNOWN | Fosun Pharma | Jun 15, 2024 | 1,550 |
How it is read
Names in the registry
- “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)”, 3 entries
- “Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)”, 3 entries
- “Azvudine tablets(FNC) and Rifampicin Capsules (RIF)”, 3 entries
- “Azvudine tablets”, 2 entries
- “Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)”, 2 entries
Conditions, from the studies’ own filings
- COVID-19, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.